1. Home
  2. GDV vs TRVI Comparison

GDV vs TRVI Comparison

Compare GDV & TRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Gabelli Dividend & Income Trust of Beneficial Interest

GDV

Gabelli Dividend & Income Trust of Beneficial Interest

HOLD

Current Price

$28.79

Market Cap

2.6B

Sector

Finance

ML Signal

HOLD

Logo Trevi Therapeutics Inc.

TRVI

Trevi Therapeutics Inc.

HOLD

Current Price

$17.52

Market Cap

2.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GDV
TRVI
Founded
2003
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.6B
2.1B
IPO Year
N/A
2019

Fundamental Metrics

Financial Performance
Metric
GDV
TRVI
Price
$28.79
$17.52
Analyst Decision
Strong Buy
Analyst Count
0
11
Target Price
N/A
$21.55
AVG Volume (30 Days)
131.9K
1.4M
Earning Date
01-01-0001
05-05-2026
Dividend Yield
5.81%
N/A
EPS Growth
N/A
31.91
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$25.73
$5.41
52 Week High
$29.58
$18.16

Technical Indicators

Market Signals
Indicator
GDV
TRVI
Relative Strength Index (RSI) 44.42 72.24
Support Level $28.73 $10.07
Resistance Level $28.85 N/A
Average True Range (ATR) 0.41 0.86
MACD -0.02 0.43
Stochastic Oscillator 42.44 87.21

Price Performance

Historical Comparison
GDV
TRVI

About GDV Gabelli Dividend & Income Trust of Beneficial Interest

Gabelli Dividend & Income Trust operates as a diversified closed-end management investment company. The fund's investment objective is to provide a high level of total return on its assets with an emphasis on dividends and income. To achieve its objective, the fund may invest its assets in dividend-paying securities or other income-producing securities. The fund invests in various sectors, including Financial Services, Food and Beverage, Health Care, Consumer Products, Electronics, and Computer Software & Services, and others.

About TRVI Trevi Therapeutics Inc.

Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, non-IPF interstitial lung disease, or non-IPF ILD, and refractory chronic cough, or RCC. Haduvio is an oral extended-release formulation of nalbuphine. The Company operates and manages its business as one reportable segment. Such a segment is the business of developing and commercializing the investigational therapy Haduvio.

Share on Social Networks: